IO Biotech

Yahoo Finance • 30 days ago

IO Biotech Announces Participation in Upcoming December Investor Conferences

NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced the Company’s participation... Full story

Yahoo Finance • last month

IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in overall population and across virtually all subgroups, although statistical significance on the PFS... Full story

Yahoo Finance • last month

IO Biotech Announces Participation in Upcoming Investor Conferences

NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that members of its senior... Full story

Yahoo Finance • 2 months ago

IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Pre-clinical data for IO Biotech’s next T-win vaccine candidate, IO112 targeting arginase 1, demonstrates anti-tumor activity with dynamic changes in the tumor microenvironment (TME) driven by the vaccine-targeted modulation of immunosuppr... Full story

Yahoo Finance • 2 months ago

IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025

Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression free survival (PFS) primary endpoint fo... Full story

Yahoo Finance • 3 months ago

After-Hours Movers: Biotech And Medtech Stocks Jump On Volume And News

(RTTNews) - A wave of after-hours activity swept through select biotech and medical device names Thursday, with several micro- and mid-cap stocks posting sharp gains following session-end catalysts, volume spikes, or pipeline updates. Belo... Full story

Yahoo Finance • 3 months ago

IO Biotech Provides Update Following Pre-BLA Meeting with FDA

FDA recommends that IO Biotech not submit a Biologics License Application (BLA) based on the data from the IOB-013 clinical trial Company plans to design new registrational study for Cylembio for the treatment of first-line patients with a... Full story

Yahoo Finance • 3 months ago

IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025

Oral presentation will highlight the results from the randomized Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 cancer vaccine plus pembrolizumab for first-line (1L) advanced melanomaPoster presentation will share final data from Phase 2 ba... Full story

Yahoo Finance • 4 months ago

H.C. Wainwright Reiterates Buy Rating on IO Biotech, Keeps PT at $14

IO Biotech, Inc. (NASDAQ:IOBT) is one of the 11 Low Price High Volume Stocks to Buy According to Analysts. On August 15, H.C. Wainwright reiterated a Buy rating on IO Biotech, Inc. (NASDAQ:IOBT), keeping its price target at $14. Emily Bod... Full story

Yahoo Finance • 4 months ago

In today's session, these stocks are experiencing unusual volume.

Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume. [unusualvolume] UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT VMAR [https://www.chartmill.com/stock/quote/VMAR/profile]... Full story

Yahoo Finance • 4 months ago

Top movers in Friday's session

Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. [topmovers] TOP GAINERS TICKER CHANGE CO... Full story

Yahoo Finance • 4 months ago

These stocks have an unusual volume in today's session

Discover the stocks with unexpected trading volume in today's session on the US markets. [unusualvolume] UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT ADD [https://www.chartmill.com/stock/quote/ADD/profile] -29.04% 56.82M s... Full story

Yahoo Finance • 4 months ago

Top movers in Tuesday's session

Looking for insights into the US markets in the middle of the day on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT... Full story

Yahoo Finance • 4 months ago

These stocks are moving in today's after hours session

The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today. [postmarket] AFTER HOURS GAINERS TICKER CHANGE COMMENT ANY [https://www.chartmill.com/stock/qu... Full story

Yahoo Finance • 4 months ago

Which stocks are experiencing notable movement on Monday?

Curious about what's happening in today's session? Check out the latest stock movements and price changes. [topmovers] GAINERS TICKER CHANGE COMMENT EQ [https://www.chartmill.com/stock/quote/EQ/profile] 77.82% Positive ma... Full story

Yahoo Finance • 4 months ago

Let's have a look at the top gainers and losers in the middle of the day of today's session.

Here are the top movers in Monday's session, showcasing the stocks with significant price changes. [topmovers] GAINERS TICKER CHANGE COMMENT EQ [https://www.chartmill.com/stock/quote/EQ/profile] 87.56% With a 87.56% surge... Full story

Yahoo Finance • 4 months ago

BC-Most Active Stocks

NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Wang & Lee Group Inc. 319,475,864 0.069 0.0559 0.0592 +0.0134 Entero The... Full story

Yahoo Finance • 4 months ago

Monday's pre-market session: top gainers and losers

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT E... Full story

Yahoo Finance • 4 months ago

IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed

IO Biotech Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab monotherapy, HR=0.77 (CI 0.58-... Full story

Yahoo Finance • 5 months ago

IO Biotech files to sell 4.22M shares of common stock for holders

* IO Biotech (NASDAQ:IOBT [https://seekingalpha.com/symbol/IOBT]) filed a prospectus for the offer and sale of 4.22M shares of common stock by the selling stockholders.  * This prospectus is not an offer to sell these securities.  *... Full story